Kirsten Gillibrand on Bolstering Domestic Drug Production Through Economic Incentives

Incentives for Domestic Drug Manufacturing

• 💡 Senator Kirsten Gillibrand inquired about the most impactful economic incentive to encourage domestic manufacturing of medications.
• 🎯 Experts were asked to identify the primary factor limiting US operations and how current procurement rules contribute to a "race to the bottom."

Maximizing Production Volume and Capacity

• 🚀 One expert emphasized the importance of volume over price, noting that their factory produces a dose for 1.5 cents and needs to operate at full capacity (24/7) to maximize efficiency.
• 💰 A proposed solution involves a system similar to sugar, creating a carve-out marketplace with priority for domestic production to fulfill total demand.

Addressing Low-Cost Essential Drugs

• 💊 For very low-cost, essential generic drugs, creating consistent demand for US products is crucial, as current prices make them uncompetitive for domestic production without guaranteed demand.
• ⚠️ The development of these products is often contingent on drug shortages, as manufacturers don't expect to sell them at current market prices.

Challenges with Federal Procurement Rules

• 🎖️ Applying small business set-aside policies to critical medicines with supply chain vulnerabilities has negative consequences for industry, taxpayers, and patients.
• 🛡️ A company that acquired a generic antibiotic manufacturer as a national security imperative was effectively barred from selling to the federal government as a prime contractor due to these rules.
• 🌍 Current government rules prevent American manufacturers from competing while allowing foreign competitors, often subsidized by their governments, to dominate federal procurement.

Aligning Incentives for Supply Chain Reliability

• 📈 The central obstacle to restoring pharmaceutical supply chain reliability is a lack of aligned incentives, not a lack of data.
• ⚖️ Buyers are structurally rewarded for choosing the lowest immediate cost, even at the expense of long-term security and patient safety.
• ✅ Federal entities should adopt procurement policies that value supply chain reliability and strategic investment in domestic sourcing to strengthen national health security and reduce drug shortages.